GlassScriptPhysician profile
Julius Bosco
NPI 1942276878
$529.71
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.54 · 2022: $164 · 2023: $280 · 2024: $13.75.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $194 · Education: $99.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $193.68 |
| Education | $99.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $241.70 | 2019-2023 | Liletta, Lo Loestrin Fe |
| Astellas Pharma US INC | $99.99 | 2023 | |
| Hologic Sales and Service, LLC | $30.60 | 2023-2024 | Aptima |
| Amgen INC. | $30.40 | 2019-2023 | Prolia, Evenity |
| Ardelyx, INC. | $18.66 | 2023 | Ibsrela |
| Mylan Pharmaceuticals INC. | $18.28 | 2022 | |
| Mallinckrodt Enterprises LLC | $17.97 | 2019 | |
| Biohaven Pharmaceutical Holding Company LTD. | $17.82 | 2022 | |
| Mayne Pharma Commercial LLC | $13.42 | 2022 | |
| Boston Scientific Corporation | $12.75 | 2019 | |
| Therapeuticsmd, INC. | $12.15 | 2022 | |
| Amag Pharmaceuticals, INC. | $10.92 | 2019 | |
| Organon LLC | $5.05 | 2023 | Nexplanon |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Julius Bosco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.